ScreenerHero

IBIOiBio, Inc.

NAS · US · Healthcare · Biotechnology · ibioinc.com
1.430USD-4.03%Mkt Cap: 71.04M $P/E: —

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include Eng…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap71.04M $
Enterprise Value555.48K $
Revenue (TTM)300.00K $
Gross Profit300.00K $
Net Income (TTM)-18.38M $
Revenue/Share0.0040 USD
Last Price1.430 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4510336096
Valuation
P/E (Trailing)—
P/E (Forward)-4.74
PEG—
EV/EBITDA-0.02
EV/Revenue1.85
P/S243.42
P/B0.65
EPS (TTM)-0.55
EPS (Forward)-0.31
52W Range
0.670024% of range3.820
52W High3.820 USD
52W Low0.6700 USD
Profitability
Gross Margin100.00%
Oper. Margin-9653.00%
EBITDA Margin0.00%
Profit Margin-4594.25%
ROE-123.50%
ROA-79.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.30M $
CapEx (TTM)16.00K $
FCF Margin-5081.25%
FCF Yield-21.46%
Net Debt-72.47M $
Net Debt/EBITDA2.56
Balance Sheet
Debt/Equity0.24
Current Ratio11.88
Quick Ratio11.50
Book Value/Sh2.245 USD
Cash/Share1.506 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 11, 2018
Splits
Last Split1:20
Split DateNov 29, 2023
Analyst Consensus
Rating—
Target (Mean)5.400 USD
Upside (mean)+277.6%
Target Range4.200 USD – 7.000 USD
$4.200+277.6% to mean$7.000
# Analysts8
Ownership
Shares Out.49.68M
Float34.88M
Insiders1.71%
Institutions71.75%
Short Interest
Short Ratio5.2d
Short % Float10.33%
Short % Out.10.28%
Shares Short5.11M
Short (prev mo.)4.69M
Technical
SMA 501.512 (-5.4%)
SMA 2001.840 (-22.3%)
Beta1.31
S&P 52W Chg18.16%
Avg Vol (30d)695.43K
Avg Vol (10d)912.06K
Technical Indicators
RSI (14)47.3
MACD-0.0166
MACD Signal-0.0303
MACD Hist.+0.0137
BB Upper1.490 USD
BB Middle1.422 USD
BB Lower1.354 USD
BB Width9.55%
ATR (14)0.0907 USD
Vol Ratio (20d)1.24x